Search

Your search keyword '"Matthew Wintle"' showing total 22 results

Search Constraints

Start Over You searched for: Author "Matthew Wintle" Remove constraint Author: "Matthew Wintle"
22 results on '"Matthew Wintle"'

Search Results

1. Metabolic effects of the incretin mimetic exenatide in the treatment of type 2 diabetes

2. Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration

3. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

4. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

5. Exenatide effects on glucose metabolism and metabolic disorders common to overweight and obese patients with type 2 diabetes

6. Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin-4) in Healthy Subjects

7. PDB11 Glycemic Outcomes Among Patients Receiving Exenatide BID or Liraglutide for Type 2 Diabetes in Clinical Practice: A Retrospective Analysis of the GE Centricity EMR Data

8. Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting

9. A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

10. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine

11. DB3 REAL-WORLD ANALYSIS OF PERCENT OF PATIENTS WITH TYPE 2 DIABETES ACHIEVING GLYCEMIC GOAL WITH INSULIN GLARGINE

13. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes

14. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data

15. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4)

16. 40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

17. PDB4 MODELING HEALTH AND ECONOMIC OUTCOMES ASSOCIATED WITH EXENATIDE ONCE-WEEKLY VERSUS INSULIN AND PIOGLITAZONE TREATMENT FOR TYPE-2 DIABETES

18. PDB58 CHANGES IN CONCOMITANT DIABETES THERAPIES ASSOCIATED WITH THE INITIATION OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES

19. Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.

20. Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States: An Adjunctive Treatment for Type 2 Diabetes Mellitus

Catalog

Books, media, physical & digital resources